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Abstract 2-Thiouracil (TU), an established antithyroid drug
and melanoma-seeker, was found to selectively inhibit neuronal
nitric oxide synthase (nNOS) in a competitive manner (Ki = 20
WM), being inactive on the other NOS isoforms. The drug
apparently interfered with the substrate- and tetrahydrobiopterin
(BH4)-binding to the enzyme. It caused a 60% inhibition of
H2O2 production in the absence of L-arginine and BH4, and
antagonised BH4-induced dimerisation of nNOS, but did not
affect cytochrome c reduction. These results open new perspec-
tives in the understanding of the antithyroid action of TU and
provide a new lead structure for the development of selective
nNOS inhibitors to elucidate the interdependence of the substrate
and pteridine sites and to modulate pathologically aberrant NO
formation. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Nitric oxide synthase (NOS) is a haem-containing enzyme
that catalyses the NADPH-dependent formation of nitric ox-
ide (nitrogen monoxide, NO) from L-arginine and O2 [1^3].
NOS occurs in at least three distinct isoforms, a Ca2/calmod-
ulin-dependent neuronal isoform (nNOS, type I NOS), a
Ca2-independent, inducible isoform (iNOS, type II NOS),
and a Ca2/calmodulin-dependent, endothelial isoform
(eNOS, type III NOS). The physiological activation of these
isoforms ensures supply of NO to ful¢l a variety of signalling
functions, e.g. in neurotransmission, macrophage-dependent
immune response and vascular relaxation. However, overacti-
vation of certain NOS isoforms has been implicated in several
pathological states, including septic shock [4] and tissue dam-
age secondary to in£ammatory conditions [5]. The modulation
of NO synthesis through selective inhibition of the various
NOS isoforms is therefore a promising therapeutic strategy
and a valuable means to de¢ne the relative involvement of
these enzymes in biological systems [6]. The research and clin-
ical utility of this approach is well apparent in the case of
neurological conditions, especially ischaemia/reperfusion and
vasospasm secondary to subarachnoid haemorrhage, where
recognition of the pathophysiological role of nNOS has war-
ranted considerable interest toward novel selective inhibitors
of this isoform [7].
Functionally active nNOS is homodimeric and each subunit
contains a reductase domain that binds NADPH, FAD and
FMN, and an oxygenase domain, that binds haem, the sub-
strate L-arginine and tetrahydrobiopterin (BH4) [2,3]. Electron
£ow from the reductase domain to the haem in the oxygenase
domain is triggered by the binding of calmodulin and results
in L-arginine oxidation and NO synthesis. NOS can catalyse
two additional NADPH-dependent reactions, namely reduc-
tion of cytochrome c, requiring only the reductase domain,
and activation of molecular oxygen, leading to the production
of superoxide and H2O2.
The role of BH4 as cofactor is still not entirely elucidated,
but seems to involve allosteric activation of the enzyme with
promotion of L-arginine binding, shift of the haem from the
low-spin to high-spin state and stabilisation of the homodi-
meric form [2,3,8,9]. The major outcome of these BH4-in-
duced changes is the coupling of NADPH oxidation to NO
synthesis. Whether BH4 controls this process by being chemi-
cally involved as a redox active agent is unclear [2], though
recent evidence suggests that BH4 is consumed during catal-
ysis in nNOS [10] and may be involved in redox cycling pro-
cesses [11].
The increasing interest in the role(s) of BH4 as NOS cofac-
tor has drawn considerable attention toward BH4 antagonists
as useful tools to probe the pteridine binding pocket and its
allosteric interactions with the L-arginine binding site, as well
as to control aberrant NO production [12^14]. We report
herein that 2-thiouracil (TU), an established antithyroid
drug [15] and an extensively investigated agent for the early
detection and targeting of metastatic melanotic melanoma
[16^18], is a highly selective inhibitor of nNOS which specif-
ically antagonises BH4-dependent enzyme activation.
2. Materials and methods
2.1. Materials
TU, uracil, thiourea were from Aldrich (Italy). Calmodulin,
NADPH, FAD, FMN, BH4 were from Sigma (Italy). Radiolabelled
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L-[U-14C]arginine monohydrochloride (317 mCi/mmol) was obtained
from Amersham Italia (Italy). Recombinant rat nNOS and mouse
iNOS were from Alexis Italia (Italy). Recombinant bovine eNOS
was from Cayman (USA).
2.2. Enzyme preparation
Rat cerebellum extract was prepared as previously described [19].
2.3. NOS activity assays
2.3.1. L-[14C]Citrulline formation. NOS activity was determined
by monitoring the conversion of L-[U-14C]arginine to L-[U-14C]-
citrulline. In the case of rat cerebellum extract, the reaction mixtures
were prepared as previously described [20]. For nNOS, aliquots (2 Wl,
0.18 Wg protein) of commercial recombinant enzyme were incubated
for 15 min at 37‡C in 0.1 ml of 20 mM Tris^HCl, pH 7 containing
0.5 mM NADPH, 250 WM calcium chloride, 1 WM BH4, 10 Wg/ml
calmodulin, 5 WM FAD, 5 WM FMN and 1.56 WM L-[U-14C]arginine.
In all cases, each reaction was stopped by the addition of 0.9 ml of
ice-cold 100 mM HEPES bu¡er containing 4 mM EDTA, pH 5.5 and
passed through 1 ml Dowex 50 (Na form) column that retains argi-
nine. [14C]citrulline generated was eluted with water and quanti¢ed by
liquid scintillation counting.
For inhibitor selectivity experiments toward NOS isoforms, compa-
rable units of the three isoforms were assayed under the same exper-
imental conditions.
Reversibility of NOS inhibition by TU was tested according
to Garvey et al. [21]. Brie£y, nNOS was preincubated at 4‡C for
10 min in the presence of cofactors with or without 500 WM TU.
The reaction was then started by the addition of L-arginine and por-
tions of the mixture were removed at various intervals of time and
assayed for NOS activity.
2.3.2. NO formation. In some experiments NOS activity was also
assessed by measuring NO metabolites, nitrate and nitrite. Aliquots
(3 Wl, 2.7 Wg protein) of commercial recombinant nNOS were incu-
bated for 15 min at 37‡C with 50 Wl of 20 mM Tris^HCl, pH 7
containing 0.5 mM NADPH, 250 WM calcium chloride, 1 WM BH4,
10 Wg/ml calmodulin, 5 WM FAD, 5 WM FMN and 100 WM L-arginine
in the presence or in the absence of 1 mM TU. NO formation was
determined by quantitative analysis of nitrate/nitrite in the incubation
medium with the NO colourimetric test from Boehringer Mannheim
Italia, Italy.
2.3.3. H2O2 formation by nNOS. Hydrogen peroxide was deter-
mined by the ferrous thiocyanate assay [22].
2.3.4. Cytochrome c reductase activity of nNOS. NADPH-depen-
dent reduction of cytochrome c in the absence of calcium and cal-
modulin was determined spectrophotometrically as previously de-
scribed [23].
2.4. HPLC analysis
The stability of TU was determined by HPLC on a Gilson model
302 instrument, using a Sphereclone 5 Wm ODS2 column (250U4.60
mm) (Phenomenex Chemtek Analytica, Bologna, Italy). The mobile
phase was 0.05 M sodium citrate bu¡er, pH 2.5, containing 5% ace-
tonitrile. The £ow rate was maintained at 1 ml/min. Detection was
carried out at 280 nm with a Gilson model 116 UV detector.
2.5. PAGE
Formation of stable nNOS dimers was analysed by low-tempera-
ture SDS^PAGE as described [9]. Recombinant nNOS was incubated
for 10 min at 37‡C in 20 Wl of 50 mM triethanolamine^HCl bu¡er
(pH 7) in the absence and presence of compounds as indicated. In-
cubations were terminated by the addition of chilled Laemmli bu¡er
[24] containing 0.125 M Tris^HCl (pH 6.8), 4% (w/v) SDS, 10% (v/v)
2-mercaptoethanol, 20% (w/v) glycerol and 0.02% (w/v) bromophenol
blue. Samples containing 2.25 Wg of proteins were subjected to SDS^
PAGE for 110 min at 150 V on discontinuous 6% SDS slab gels. Gels
and bu¡ers, prepared according to Laemmli [24], were equilibrated at
4‡C and the bu¡er tank was cooled during electrophoresis in an ice
bath. Gels were stained for protein detection with silver using the
silver stain plus kit from Bio-Rad.
3. Results
Incubation of recombinant nNOS with TU resulted in
a marked, concentration-dependent inhibition of the enzyme
activity (IC50 = 50 þ 5 WM), as determined by the L-[14C]-
arginine conversion assay (Fig. 1). The inhibitory e¡ect was
con¢rmed by determination of the main NO metabolites, ni-
trate and nitrite, accumulated in the reaction mixture [2]. With
100 WM L-arginine and 54 Wg/ml of recombinant enzyme,
51 þ 2% (average of three separate experiments) inhibition of
NO formation was observed with 1 mM TU. The high en-
zyme, substrate and TU concentrations were warranted by the
relatively low sensitivity of the colourimetric assay used (see
experimental). Comparable inhibitory e¡ects of TU were ob-
served on the NOS activity in rat cerebellum extracts. At 500
WM concentration the parent thioureylene compound, thio-
urea, and uracil, which lacks the sulphur atom, were ine¡ec-
tive in inhibiting nNOS activity.
Interestingly, TU proved to be highly selective for nNOS,
being poorly active toward iNOS (less than 25% inhibition)
and eNOS (less than 15% inhibition) at a concentration as
high as 500 WM.
The progress curve for inhibited nNOS was linear, the onset
of inhibition was rapid and citrulline formation increased al-
most linearly during a 15 min incubation time (data not
shown), suggesting that inhibition by TU was reversible. In
accordance with these results, preincubation of nNOS with
Fig. 1. Concentration-dependent inhibition of nNOS by TU. NOS
activity was measured as the production of L-[14C]citrulline from
L-[14C]arginine as described in Section 2. Results are means þ S.E.M.
from four experiments.
Fig. 2. Double reciprocal plot of nNOS activity as a function of
L-arginine concentrations, in the presence of various concentrations
of TU. The rate of L-[14C]citrulline formation was measured as de-
scribed in Section 2 in the absence (E) or in the presence of 12.5
(b) or 25 (R) or 50 WM (F) TU. The plot shown is representative
of three.
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500 WM TU for 10 min prior to initiation of the reaction with
1.56 WM L-arginine did not cause additional inhibition, ruling
out any irreversible e¡ect.
Initial-rate kinetic studies were carried out over a range of
L-[14C]arginine and TU concentrations to determine the na-
ture of nNOS inhibition. Double-reciprocal plots of the nNOS
activity as a function of L-arginine concentration showed that
TU inhibits L-citrulline formation in an essentially competitive
manner (Fig. 2).
Replots of reciprocal rates of L-citrulline formation against
TU concentration at a series of ¢xed arginine concentrations
gave straight lines intersecting on the ordinate axis, which
allowed determination of a Ki value of 20 WM. Consistent
with a competitive-type mechanism, inhibition of nNOS by
500 WM TU was decreased by ca. 50% with saturating L-argi-
nine concentrations (e.g. 200 WM).
At 100 WM concentration, TU did not a¡ect cytochrome c
reduction in the absence of Ca2/calmodulin, but caused ca.
60% inhibition of H2O2 production in the absence of L-argi-
nine and BH4. In control experiments, HPLC analysis of TU
and peroxide determination ruled out any direct reaction of
TU with H2O2 under the speci¢c conditions of the assay.
The inhibitory e¡ect of TU on L-citrulline formation could
be reverted by BH4 in a concentration-dependent manner
(Fig. 3). In particular, nNOS inhibition by 0.5 mM TU was
decreased to a constant value (ca. 36%) at BH4 concentrations
v3 WM. The possibility that this e¡ect re£ected decomposition
of TU by BH4 was ruled out by HPLC analysis, demonstrat-
ing that the drug (500 WM) is fairly stable even when incu-
bated with as much BH4 as 100 WM under the speci¢c con-
ditions of the assay.
The plateau e¡ect in Fig. 3 is di⁄cult to explain based on
available data. Apparently, it would denote a tight and com-
plex interaction of TU with the BH4 binding site, a¡ecting
BH4-dependent enzyme activation at various levels and with
di¡erent modalities [2].
In this connection, separate experiments showed that TU
a¡ected BH4-dependent nNOS dimerisation, that is critical for
enzyme activity [2,3]. Low temperature SDS^PAGE analysis
[9], displayed in Fig. 4, showed that at 500 WM concentration
TU markedly decreased the amount of nNOS dimer (320 kDa
band) formed in the presence of 1 WM BH4 (lane C versus lane
B). Notably, the inhibitory e¡ect of 500 WM TU on enzyme
dimerisation was virtually suppressed when BH4 concentra-
tion was raised to 10 WM (lane E versus lane D). No dimer
formation was induced by TU in the absence of BH4 (lane F).
4. Discussion
The antithyroid and melanoma targeting properties of TU
have been related to its inhibitory e¡ects on distinct enzymatic
activities, including thyroid iodide peroxidase [25], myeloper-
oxidase, eosinophil peroxidase [26] and tyrosinase [27]. Our
¢nding that TU is also a selective inhibitor of nNOS prevent-
ing BH4-dependent dimerisation discloses a hitherto unrecog-
nised property of this drug of potential relevance to the mech-
anism of the antithyroid action, in view of the recent
demonstration of NOS activity in the thyroid gland [28].
TU may also represent a useful prototype for the rational
design of novel neuroprotective agents for the treatment of
cerebral ischaemia and other neurological disorders, with an
advantage over other nNOS inhibitors derived from having a
well known pharmacological pro¢le.
The competitive pattern of inhibition and the antagonising
e¡ects of BH4 would be consistent with TU interacting with a
site located proximal to the BH4 and L-arginine binding sites,
possibly the haem or its periphery. In accord with this inter-
pretation, the drug inhibited haem-catalysed oxygen activa-
tion and H2O2 production, but not cytochrome c reduction,
indicating that it did not a¡ect the reductase domain. In ad-
dition, TU has been reported to perturb the haem environ-
ment of another enzyme, horseradish peroxidase [29].
The inhibitory properties of TU can be ascribed to the
presence of the thioureylene moiety, a feature shared also
by the haem-binding NOS inhibitor L-thiocitrulline [23]. How-
ever, this moiety per se is unlikely to account for nNOS inhi-
bition, as indicated by the lack of e¡ects of thiourea, although
the sulphur centre seems essential, since uracil was inactive.
Similarly di¡erent e¡ects of TU and uracil have been de-
Fig. 3. E¡ect of BH4 concentration on nNOS inhibition by TU.
The enzyme was incubated with increasing BH4 concentrations in
the presence of 500 WM TU and NOS activity was measured as de-
scribed in Section 2. Results are means þ S.E.M. from four experi-
ments.
Fig. 4. E¡ect of TU on BH4-induced nNOS dimerization. nNOS
was incubated, as described in Section 2, with or without BH4 in
the absence or presence of TU (500 WM), followed by low-tempera-
ture SDS^PAGE analysis. From left to right: lane A, no BH4 ; lane
B, 1 WM BH4 ; lane C, 1 WM BH4+TU; lane D, 10 WM BH4 ; lane
E, 10 WM BH4+TU; lane F, TU. NOS and Di-NOS refer to nNOS
monomer and dimer with apparent molecular masses of approxi-
mately 160 and 320 kDa, respectively. The gel shown is representa-
tive of three separate experiments.
Fig. 5. Structures of TU and BH4.
FEBS 24297 17-11-00
A. Palumbo et al./FEBS Letters 485 (2000) 109^112 111
scribed in the case of horseradish peroxidase [29]. Since at
physiological pH, TU is in equilibrium with the anionic
form (pKa = 7.75), it can be engaged in strong ionic-type in-
teractions and/or H-bonding with polar residues within the
BH4 binding site, while being able to maintain contact with
£at aromatic moieties through Z-electron stacking and related
interactions [12]. Thus, because of its loose structural resem-
blance to the pyrimidine moiety of BH4 (Fig. 5) and its redox
stability, TU may replace BH4 at the pteridine binding site
without however being able to sustain redox processes and/or
prevent enzyme monomerisation during L-arginine turnover
[10].
The action pro¢le of TU is peculiar and reminiscent of that
of 7-nitroindazole [14,30]. TU may therefore provide an at-
tractive lead structure for novel selective nNOS inhibitors
aimed at probing the delicate interplay between the tightly
coupled pteridine- and substrate-binding domains. Moreover,
given the di¡erent dependence of the various isoforms of NOS
on BH4 activation, TU would represent a superior biochem-
ical tool to di¡erentiate the physiopathological roles of the
various isoforms in vivo.
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